

REGISTERED NUMBER: 06508826 (England and Wales)

**UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020
FOR
RADPHARM MANAGEMENT LIMITED**

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Page
Company Information	1
Statement of Financial Position	2
Notes to the Financial Statements	4

RADPHARM MANAGEMENT LIMITED

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2020**

DIRECTORS:

Mrs S Radia
Mr S C Radia

REGISTERED OFFICE:

Unit 2.02
High Weald House
Glovers End
Bexhill
East Sussex
TN39 5ES

REGISTERED NUMBER:

06508826 (England and Wales)

ACCOUNTANTS:

Acuity Professional Partnership LLP
Unit 2.02
High Weald House
Glovers End
Bexhill
East Sussex
TN39 5ES

STATEMENT OF FINANCIAL POSITION
31 DECEMBER 2020

		2020		2019	
	Notes	£	£	£	£
FIXED ASSETS					
Investments	4		2,383,416		2,348,214
CURRENT ASSETS					
Debtors	5	1,131,001		906,163	
Cash at bank		<u>24,078</u>		<u>19,212</u>	
		1,155,079		925,375	
CREDITORS					
Amounts falling due within one year	6	<u>1,653,515</u>		<u>1,538,677</u>	
NET CURRENT LIABILITIES			<u>(498,436)</u>		<u>(613,302)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>1,884,980</u>		<u>1,734,912</u>
CAPITAL AND RESERVES					
Called up share capital	7		100		100
Retained earnings		<u>1,884,880</u>		<u>1,734,812</u>	
SHAREHOLDERS' FUNDS		<u>1,884,980</u>		<u>1,734,912</u>	

The notes form part of these financial statements

STATEMENT OF FINANCIAL POSITION - continued
31 DECEMBER 2020

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 September 2021 and were signed on its behalf by:

Mr S C Radia - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

1. STATUTORY INFORMATION

Radpharm Management Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

TURNOVER

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

INVESTMENTS IN SUBSIDIARIES

Investments in subsidiary undertakings are recognised at cost.

TAXATION

Taxation for the year comprises of current tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2019 - 2) .

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020

4. FIXED ASSET INVESTMENTS

	Shares in group undertakings £	Listed investments £	Totals £
Cost or valuation			
At 1 January 2020	1,326,374	1,021,840	2,348,214
Additions	-	299,135	299,135
Disposals	-	(304,414)	(304,414)
Revaluations	-	40,481	40,481
At 31 December 2020	<u>1,326,374</u>	<u>1,057,042</u>	<u>2,383,416</u>
Net book value			
At 31 December 2020	<u>1,326,374</u>	<u>1,057,042</u>	<u>2,383,416</u>
At 31 December 2019	<u>1,326,374</u>	<u>1,021,840</u>	<u>2,348,214</u>

Cost or valuation at 31 December 2020 is represented by:

	Shares in group undertakings £	Listed investments £	Totals £
Valuation in 2019	<u>1,326,374</u>	<u>1,057,042</u>	<u>2,383,416</u>

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Amounts owed by group undertakings	158,101	158,101
Other debtors	797,244	722,244
Directors' current accounts	146,425	-
VAT	<u>29,231</u>	<u>25,818</u>
	<u>1,131,001</u>	<u>906,163</u>

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Amounts owed to group undertakings	1,621,147	1,486,318
Tax	27,868	47,561
Directors' current accounts	-	397
Accruals and deferred income	<u>4,500</u>	<u>4,401</u>
	<u>1,653,515</u>	<u>1,538,677</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2020 £	2019 £
100	Ordinary	£1	<u>100</u>	<u>100</u>

8. RELATED PARTY DISCLOSURES

During the year, total dividends of £11,750 (2018: £12,000) were paid to the directors.

At the year end, an amount of £1,621,147 (2019: £1,486,318) was owed to Radpharm Ltd, a wholly owned subsidiary of Radpharm Management Ltd.

9. ULTIMATE CONTROLLING PARTY

The company is under the joint control of Mr and Mrs S Radia, its directors, by virtue of their shareholding.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.